Estrone (Synonyms: E1) |
| Catalog No.GC14385 |
Estrone is one of the three major endogenous estrogens, the others being estradiol and estriol.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53-16-7
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Estrone is one of the three major endogenous estrogens, the others being estradiol and estriol[1]. Estrone is synthesized from cholesterol and is primarily secreted by the gonads, but can also be formed by adrenal androgens in adipose tissue[2]. Estrone is an agonist of the estrogen receptor[3]. Estrone can effectively activate multiple signaling and functional responses in pituitary cells at low physiological concentrations[4].
In vitro, treatment of human endothelial colony-forming cells (hECFCs) with Estrone (0-1µM) for 24h significantly promoted cell proliferation at concentrations of 1nM and 10nM, and inhibited proliferation at a concentration of 1µM[5]. Treatment of bone progenitor cells with Estrone (10nM) upregulated the expression of estrogen receptor α (ER-α) and estrogen receptor β (ER-β), but downregulated the expression of osteopontin (OPN)[6]. Estrone (10-3-105nM) treated mouse colon cancer MC38 cells for 24-72h inhibited cell growth in a dose- and time-dependent manner[7].
In vivo, subcutaneous injection of Estrone (0.5mg/kg) in rats with traumatic brain injury reduced cortical lesion volume and neuronal damage, reduced the level of TUNEL-positive staining in the cerebral cortex, reduced the number of TUNEL-positive cells in the corpus callosum, and reduced the cortical level of β-amyloid protein after brain injury[8].
References:
[1] Bennink H J T C. Are all estrogens the same?[J]. Maturitas, 2004, 47(4): 269-275.
[2] Tchernof A, Mansour M F, Pelletier M, et al. Updated survey of the steroid-converting enzymes in human adipose tissues[J]. The Journal of steroid biochemistry and molecular biology, 2015, 147: 56-69.
[3] Eyster K M. The estrogen receptors: an overview from different perspectives[J]. Estrogen Receptors: Methods and Protocols, 2016: 1-10.
[4] Watson C S, Jeng Y J, Kochukov M Y. Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation[J]. The FASEB Journal, 2008, 22(9): 3328.
[5] Ivory A, Greene A S. Distinct roles of estrone and estradiol in endothelial colony‐forming cells[J]. Physiological Reports, 2023, 11(19): e15818.
[6] Park J B. Effects of low doses of estrone on the proliferation, differentiation and mineralization of osteoprecursor cells[J]. Experimental and Therapeutic Medicine, 2012, 4(4): 681-684.
[7] Motylewska E, Mełeń-Mucha G. Estrone and progesterone inhibit the growth of murine MC38 colon cancer line[J]. The Journal of steroid biochemistry and molecular biology, 2009, 113(1-2): 75-79.
[8] Gatson J W, Liu M M, Abdelfattah K, et al. Estrone is neuroprotective in rats after traumatic brain injury[J]. Journal of neurotrauma, 2012, 29(12): 2209-2219.
| Cell experiment [1]: | |
|
Cell lines |
Human endothelial colony-forming cells (hECFCs) |
|
Preparation Method |
5×104 serum starved hECFCs were seeded into 24 wells plates and incubated with IncuCyte® NucLight Rapid Red Reagent for nuclear labeling. Celprogen media with serum and antibiotics was supplemented with the desired treatment. Treatment groups included: Estrone, estradiol, or 1 to 1 ratio combination of Estrone/estradiol at 0nM (medium control), 1nM, 10nM, 100nM, and 1µM. The hECFCs were then incubated for 24h during which the cells were imaged in the IncuCyte SX5 Live-Cell Analysis System (Sartorius). Cell number was then quantified and presented as percentage of control. |
|
Reaction Conditions |
1nM, 10nM, 100nM, 1µM; 24h |
|
Applications |
The effect of Estrone on hECFC proliferation was biphasic with only exposures of 1nM and 10nM resulting in significant increases in hECFC proliferation. Estrone exposure at 1μM resulted in attenuated proliferation and resulted in a significantly lower hECFC cell number than control. |
| Animal experiment [2]: | |
|
Animal models |
Sprague-Dawley rats |
|
Preparation Method |
The Benchmark Stereotaxic Impactor was used to administer severe TBI in rats. An incision was made to expose the skull, and the craniotomy procedure was performed. Following the craniotomy procedure, a cortical contusion was delivered to the right hemisphere via a vertically-directed pneumatic cylinder. The skin was closed with surgical wound clips. At 30min following brain injury, the animals were treated subcutaneously with Estrone (0.5mg/kg) or vehicle (corn oil). Control and sham (craniotomy only) animals were also included as controls. The animals were monitored for pain every 6h for the first 24h, and once a day thereafter. At 72h following injury, the animals were perfusedintracardially with 0.9% saline followed by 10% phosphate-buffered formalin. The whole brain was removed, sliced, and stained for TUNEL-positive cells. |
|
Dosage form |
0.5mg/kg; s.c. |
|
Applications |
Estrone decreased cortical lesion volume and neuronal injury, and it reduced cerebral cortical levels of TUNEL-positive staining, and decreased numbers of TUNEL-positive cells in the corpus callosum. |
|
References: |
|
| Cas No. | 53-16-7 | SDF | |
| Synonyms | E1 | ||
| Chemical Name | (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one | ||
| Canonical SMILES | CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O | ||
| Formula | C18H22O2 | M.Wt | 270.37 |
| Solubility | ≥ 9.75 mg/mL in DMSO, ≥ 9.2 mg/mL in EtOH with ultrasonic and warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6986 mL | 18.4932 mL | 36.9864 mL |
| 5 mM | 0.7397 mL | 3.6986 mL | 7.3973 mL |
| 10 mM | 0.3699 mL | 1.8493 mL | 3.6986 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *